<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551733</url>
  </required_header>
  <id_info>
    <org_study_id>CTI-PGT-07-00400</org_study_id>
    <secondary_id>CDR0000573340</secondary_id>
    <secondary_id>EUDRACT-2007-004167-22</secondary_id>
    <nct_id>NCT00551733</nct_id>
  </id_info>
  <brief_title>Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer</brief_title>
  <official_title>Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol &gt;30 pg/mL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CTI BioPharma</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, and paclitaxel&#xD;
      poliglumex, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. It is not yet known whether giving carboplatin&#xD;
      together with paclitaxel poliglumex is more effective than giving carboplatin together with&#xD;
      paclitaxel in treating non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel poliglumex to&#xD;
      see how well they work compared with carboplatin and paclitaxel in treating women with stage&#xD;
      III, stage IV, or recurrent non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the overall survival of patients with chemotherapy-naïve stage IIIB or IV or&#xD;
           recurrent non-small cell lung cancer treated with paclitaxel poliglumex and carboplatin&#xD;
           vs paclitaxel and carboplatin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the progression-free survival of women treated with these regimens.&#xD;
&#xD;
        -  Compare the disease control in women treated with these regimens.&#xD;
&#xD;
        -  Compare the clinical benefit in women treated with these regimens.&#xD;
&#xD;
        -  Compare the response rate in women treated with these regimens.&#xD;
&#xD;
        -  Compare the quality of life of women treated with these regimens.&#xD;
&#xD;
        -  Compare the safety and tolerability in women treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients are stratified according to age (≥ 60 vs &lt; 60 years old), geographical location&#xD;
      (United States of America, Canada, or Australia vs the rest of the world), extent of disease&#xD;
      (independent of brain metastases, i.e., brain metastases are not considered in determining&#xD;
      extent of disease) (intrathoracic disease only vs extrathoracic disease), and ECOG&#xD;
      performance status (0 or 1 vs 2). Patients will be randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive paclitaxel poliglumex IV over 10 minutes followed by carboplatin&#xD;
           IV over 30 minutes on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30&#xD;
           minutes on day 1.&#xD;
&#xD;
      In both arms, treatment repeats every 21 days for up to 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, before each course, and at the completion of study&#xD;
      treatment by the Pain Assessment Patient Questionnaire, the Pulmonary Symptom Index, and the&#xD;
      Functional Assessment of Cancer Therapy- Lung Cancer Subscale (FACT-LCS) (only in countries&#xD;
      in which a validated translation is currently available).&#xD;
&#xD;
      After completion of study therapy, patients are followed at least monthly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">August 2007</start_date>
  <completion_date type="Actual">December 25, 2007</completion_date>
  <primary_completion_date type="Actual">December 25, 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit as defined by use of opiates, growth factors, and transfusions,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate as assessed by complete response or partial response per RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by Fact-LCS Scores and Pulmonary Symptom Index (PSI) Scores and Pain Scores</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by NCI CTCAE Version 3</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel poliglumex IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel poliglumex</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of non-small cell lung cancer&#xD;
             (NSCLC)&#xD;
&#xD;
               -  Cytologic specimens obtained by brushings, washings, or needle aspiration of a&#xD;
                  defined lesion or from a pleural effusion are acceptable; sputum cytology alone&#xD;
                  is not acceptable for determining cell type&#xD;
&#xD;
          -  Must meet one of the following criteria:&#xD;
&#xD;
               -  Recurrent disease following completion of radiation or surgery&#xD;
&#xD;
               -  Stage IIIB disease and not a candidate for combined modality therapy (primary&#xD;
                  radiation therapy or surgery)&#xD;
&#xD;
               -  Stage IV disease&#xD;
&#xD;
          -  Patients may have either measurable or nonmeasurable disease according to RECIST&#xD;
             criteria&#xD;
&#xD;
          -  Baseline estradiol &gt; 30 pg/mL&#xD;
&#xD;
               -  Patients on hormone replacement therapy are eligible provided baseline estradiol&#xD;
                  &gt; 30 pg/mL&#xD;
&#xD;
          -  Patients with known brain metastases must have received standard antitumor treatment&#xD;
             (e.g. whole brain radiation, stereotactic radioablation, or surgery) for their CNS&#xD;
             metastases as defined by the site's institutional standards&#xD;
&#xD;
               -  Neurologic function must have been stable for 2 weeks before randomization and&#xD;
                  patients must either be off steroid therapy for their brain metastases or on a&#xD;
                  tapering regimen&#xD;
&#xD;
               -  Patients must have recovered from therapy for their brain metastases with no&#xD;
                  evidence of significant unstable neurological symptoms within the 4 weeks before&#xD;
                  study randomization&#xD;
&#xD;
          -  No evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell&#xD;
             histology&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  ECOG performance score 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL (may be achieved with transfusion)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times ULN (CTC grade 1) (patients with Gilbert syndrome or other&#xD;
             hereditary bilirubin defects may be included regardless of bilirubin levels)&#xD;
&#xD;
          -  SGOT and SGPT ≤ 2.5 times ULN (CTC grade 0 or 1) (5 times ULN [CTC grade 0 to 2] if&#xD;
             due to liver metastases)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN except for elevated alkaline phosphatase with&#xD;
             laboratory documentation that demonstrates bone origin&#xD;
&#xD;
          -  No pregnant women or nursing mothers&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
             participation&#xD;
&#xD;
          -  No known hypersensitivity to study drugs or excipients&#xD;
&#xD;
          -  Meets all of the following criteria:&#xD;
&#xD;
               -  No weight loss &gt; 10% in previous 6 months&#xD;
&#xD;
               -  Lactate dehydrogenase (LDH) ≤ 600 IU/L (central laboratory) regardless of weight&#xD;
                  loss&#xD;
&#xD;
               -  LDH ≤ 400 IU/L (central laboratory) and no weight loss ≥ 5% in previous 6 months&#xD;
&#xD;
               -  BMI ≤ 35&#xD;
&#xD;
          -  No concurrent primary malignancies except for carcinoma in situ or non-melanoma skin&#xD;
             cancer&#xD;
&#xD;
          -  No neuropathy grade 2 or greater&#xD;
&#xD;
          -  No clinically significant active infection for which active therapy is underway&#xD;
&#xD;
          -  No unstable medical conditions including unstable angina or myocardial infarction&#xD;
             within the past 6 months&#xD;
&#xD;
               -  Patients with evidence of cardiac conduction abnormalities are eligible if their&#xD;
                  cardiac status is stable&#xD;
&#xD;
          -  No circumstance that would preclude completion of the study or the required follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from major surgery&#xD;
&#xD;
          -  At least 7 days since prior local palliative radiotherapy&#xD;
&#xD;
          -  At least 30 days since prior radiation therapy with curative intent&#xD;
&#xD;
          -  At least 4 weeks since prior investigational therapy, unless local requirements are&#xD;
             more stringent&#xD;
&#xD;
          -  No prior systemic chemotherapy for the treatment of lung cancer, including systemic&#xD;
             radiosensitizers used to treat brain metastases or any biologic agents&#xD;
&#xD;
          -  No concurrent non-protocol-specified systemic antitumor therapy&#xD;
&#xD;
          -  No concurrent amifostine, investigational agents, other cytotoxic agents for this&#xD;
             disease&#xD;
&#xD;
          -  No concurrent radiotherapy (with the exception of radiotherapy for brain or bone&#xD;
             metastases for palliative purposes or radiotherapy for a condition other than NSCLC&#xD;
             that was ongoing at the time of randomization)&#xD;
&#xD;
               -  Patients receiving palliative radiotherapy (treatment for symptomatic metastatic&#xD;
                  disease) may be treated while on study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred B. Oldham, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CTI BioPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Medical Specialists</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Cancer Care - Escondido</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025-4404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials and Research Associates, Incorporated</name>
      <address>
        <city>Montebello</city>
        <state>California</state>
        <zip>90640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Oncology Associates</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308-1414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Institute for Clinical Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Cancer Institute at Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology Associates, Limited - West</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Consultants - Naperville</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60565</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields</name>
      <address>
        <city>Olympia Fields</city>
        <state>Illinois</state>
        <zip>60461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Indiana</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medicine of Vincennes Clinical Trial Center</name>
      <address>
        <city>Vincennes</city>
        <state>Indiana</state>
        <zip>47591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Regional Cancer and Blood Center</name>
      <address>
        <city>Free Soil</city>
        <state>Michigan</state>
        <zip>49411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newland Medical Associates PC - Southfield</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48275</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic, PA at Forrest General</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Comprehensive Cancer Care Clinic</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers - South</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Cancer Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Reno</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln Medical and Mental Health Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond University Medical Center</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10310-1699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Dakota Clinic, PC</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood and Cancer Center, Incorporated</name>
      <address>
        <city>Canfield</city>
        <state>Ohio</state>
        <zip>44406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Cancer Center at Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710-1799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles M. Barrett Cancer Center at University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vita Hematology Oncology at St. Luke's Hospital</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas - Eastside</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Cancer Center, PLLC - Collierville</name>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <zip>38077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-South Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Regional Cancer Center - Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lone Star Oncology - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center at Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Hematology Oncology, PC</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Outreach Associates - Abingdon</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cell Therapeutics, Incorporated</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Leśniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):623-30. doi: 10.1097/JTO.0b013e3181753b4b.</citation>
    <PMID>18520802</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 30, 2007</study_first_submitted>
  <study_first_submitted_qc>October 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2007</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel poliglumex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

